Nightstar Therapeutics PLC (NITE):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Nightstar Therapeutics PLC (NITE) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C9415
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:35
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:イギリス
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Nightstar Therapeutics PLC (Nightstar Therapeutics), formerly Nightstar Therapeutics Ltd, is a clinical-stage gene therapy company. The company focus on developing and commercializing novel one-time treatments for patients suffering from rare inherited retinal diseases. Its lead product candidate is NSR-REP1, a candidate that is in phase 3 clinical development for the treatment of patients with choroideremia; and NSR-RPGR, a candidate that is in Phase 1/2 clinical trials for the treatment of patients with X-linked retinitis pigmentosa, an inherited X-linked recessive retinal disease. The company also develops NSR-BEST1, a candidate that is in preclinical development stage for the treatment of best vitelliform macular dystrophy; and NSR-ABCA4, a candidate that is in preclinical development stage for the treatment of Stargardt disease. It develops retinal gene therapies for patients suffering from rare inherited retinal disease. Nightstar Therapeutics is headquartered in London, the UK.

Nightstar Therapeutics PLC (NITE) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Nightstar Therapeutics PLC, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Nightstar Therapeutics PLC, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Nightstar Therapeutics PLC, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Nightstar Therapeutics PLC, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Nightstar Therapeutics PLC, Medical Devices Deals, 2012 to YTD 2018 9
Nightstar Therapeutics PLC, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Nightstar Therapeutics PLC, Pharmaceuticals & Healthcare, Deal Details 11
Venture Financing 11
NightstaRx Raises USD45 Million in Series C Financing 11
NightstaRx Raises USD35 Million in Series B Financing Round 12
Nightstar Raises Additional USD8.2 Million in Venture Financing Round 13
NightstaRx Raises US$19.8 Million In Venture Financing 14
Licensing Agreements 15
Nightstar Therapeutics Enters into Licensing Agreement with Oxford University Innovation 15
NightstaRx Enters into Licensing Agreement with Oxford University 16
NightstaRx Expands Licensing Agreement with Isis Innovation 17
NightstaRx Enters into Licensing Agreement with Oxford University Innovation 18
Equity Offering 19
Nightstar Therapeutics Raises USD86.3 Million in Public Offering of American Depository Shares 19
Nightstar Therapeutics Raises USD86.3 Million in IPO 21
Nightstar Therapeutics PLC – Key Competitors 23
Nightstar Therapeutics PLC – Key Employees 24
Nightstar Therapeutics PLC – Locations And Subsidiaries 25
Head Office 25
Other Locations & Subsidiaries 25
Recent Developments 26
Financial Announcements 26
Aug 13, 2018: Nightstar Therapeutics reports second quarter 2018 financial results and business highlights 26
Jun 06, 2018: Nightstar Therapeutics Reports First Quarter 2018 Financial Results 28
Apr 03, 2018: Nightstar Therapeutics Reports 2017 Financial Results and Business Highlights 29
Corporate Communications 31
Sep 13, 2018: Nightstar Therapeutics names Paula Cobb as Board Director 31
Product News 32
03/19/2017: NightstaRx Commences first Phase I/II Gene Therapy Clinical Trial for Patients with X-Linked Retinitis Pigmentosa 32
Clinical Trials 33
Mar 05, 2018: Nightstar Therapeutics Announces Initiation of STAR Phase 3 Registrational Trial for NSR-REP1 in Choroideremia 33
Other Significant Developments 34
Oct 09, 2018: Gene therapy breakthrough in treating a rare form of blindness 34
Appendix 35
Methodology 35
About GlobalData 35
Contact Us 35
Disclaimer 35

List of Tables
Nightstar Therapeutics PLC, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Nightstar Therapeutics PLC, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Nightstar Therapeutics PLC, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Nightstar Therapeutics PLC, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Nightstar Therapeutics PLC, Deals By Therapy Area, 2012 to YTD 2018 8
Nightstar Therapeutics PLC, Medical Devices Deals, 2012 to YTD 2018 9
Nightstar Therapeutics PLC, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
NightstaRx Raises USD45 Million in Series C Financing 11
NightstaRx Raises USD35 Million in Series B Financing Round 12
Nightstar Raises Additional USD8.2 Million in Venture Financing Round 13
NightstaRx Raises US$19.8 Million In Venture Financing 14
Nightstar Therapeutics Enters into Licensing Agreement with Oxford University Innovation 15
NightstaRx Enters into Licensing Agreement with Oxford University 16
NightstaRx Expands Licensing Agreement with Isis Innovation 17
NightstaRx Enters into Licensing Agreement with Oxford University Innovation 18
Nightstar Therapeutics Raises USD86.3 Million in Public Offering of American Depository Shares 19
Nightstar Therapeutics Raises USD86.3 Million in IPO 21
Nightstar Therapeutics PLC, Key Competitors 23
Nightstar Therapeutics PLC, Key Employees 24
Nightstar Therapeutics PLC, Subsidiaries 25

List of Figures
Nightstar Therapeutics PLC, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Nightstar Therapeutics PLC, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Nightstar Therapeutics PLC, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Nightstar Therapeutics PLC, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Nightstar Therapeutics PLC, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Nightstar Therapeutics PLC, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Nightstar Therapeutics PLC, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Nightstar Therapeutics PLC, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Nightstar Therapeutics PLC, Medical Devices Deals, 2012 to YTD 2018 9

★海外企業調査レポート[Nightstar Therapeutics PLC (NITE):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Enterprise Rent-A-Car Company:企業の戦略・SWOT・財務情報
    Enterprise Rent-A-Car Company - Strategy, SWOT and Corporate Finance Report Summary Enterprise Rent-A-Car Company - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and …
  • Medline Industries, Inc.:企業の戦略・SWOT・財務分析
    Medline Industries, Inc. - Strategy, SWOT and Corporate Finance Report Summary Medline Industries, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Maersk Line AS:企業の戦略的SWOT分析
    Maersk Line AS - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and service …
  • pSivida Corp (PSDV)-製薬・医療分野:企業M&A・提携分析
    Summary pSivida Corp (pSivida) is a specialty pharmaceutical company that offers development of miniaturized, sustained-release drug delivery products and technologies. The company’s products include iluvien, retisert and durasert. Its durasert is an injectable, miniaturized, sustained-release drug …
  • Four Seasons Hotels Ltd:企業の戦略・SWOT・財務情報
    Four Seasons Hotels Ltd - Strategy, SWOT and Corporate Finance Report Summary Four Seasons Hotels Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Viterra Inc.:企業のM&A・事業提携・投資動向
    Viterra Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Viterra Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, …
  • Ontario Teachers’ Pension Plan:企業のM&A・事業提携・投資動向
    Ontario Teachers' Pension Plan - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Ontario Teachers' Pension Plan Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers a …
  • Dechra Pharmaceuticals Plc (DPH):企業の財務・戦略的SWOT分析
    Summary Dechra Pharmaceuticals Plc (Dechra) is a manufacturer and distributor of veterinary pharmaceutical products. The company's product portfolio includes vetoryl, felimazole, thyforon, malaseb, canaural, isaderm, cardisure, comfortan, libromide, somulose, vetoryl, rapidexon, octacillin, domidine …
  • Kellwood Company, LLC:企業の戦略・SWOT・財務情報
    Kellwood Company, LLC - Strategy, SWOT and Corporate Finance Report Summary Kellwood Company, LLC - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Al Jaber Group
    Al Jaber Group - Strategy, SWOT and Corporate Finance Report Summary Al Jaber Group - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpora …
  • Icici Bank Ltd:企業の戦略・SWOT・財務分析
    Icici Bank Ltd - Strategy, SWOT and Corporate Finance Report Summary Icici Bank Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpora …
  • Apex Healthcare Berhad (AHEALTH):企業の財務・戦略的SWOT分析
    Apex Healthcare Berhad (AHEALTH) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and wea …
  • M3 Midstream LLC:石油・ガス:M&Aディール及び事業提携情報
    Summary M3 Midstream LLC (Momentum) is an independent oil and gas company that offers midstream oilfield services. The company provides services such as gas processing and treating, wellhead gathering, dehydration, fractionation, compression, and storage services for natural gas and natural gas liqu …
  • Bionik Laboratories Corp (BNKL):医療機器:M&Aディール及び事業提携情報
    Summary Bionik Laboratories Corp (Bionik) is a medical device company that designs and develops transformational technologies, prosthetics and assisted robotic products and solutions. The company provides rehabilitation technology that senses patient movements and limitations. It provides lower body …
  • Regulus Therapeutics Inc (RGLS):製薬・医療:M&Aディール及び事業提携情報
    Summary Regulus Therapeutics Inc (Regulus Therapeutics) is a biopharmaceutical company that discovers and develops microRNA based therapeutics. The company provides single stranded oligonucleotides, which are chemically synthesized chains of nucleotides that are mirror images of specific target micr …
  • Lepu Medical Technology (Beijing) Co Ltd (300003):製薬・医療:M&Aディール及び事業提携情報
    Summary Lepu Medical Technology (Beijing) Co Ltd (Lepu Medical) is a medical technology company that offers medical equipments, pharmaceutical products and healthcare services. The company’s products include cardiovascular interventional products, surgical cardiology products, peripheral interventio …
  • Tesla Inc (TSLA):企業の財務・戦略的SWOT分析
    Tesla Inc (TSLA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • NuScale Power LLC:企業の戦略的SWOT分析
    NuScale Power LLC - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and serv …
  • Fujimori Kogyo Co., Ltd. (7917):企業の財務・戦略的SWOT分析
    Fujimori Kogyo Co., Ltd. (7917) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weak …
  • Oneok Inc (OKE):石油・ガス:M&Aディール及び事業提携情報
    Summary Oneok Inc (ONEOK) is an oil and gas company that processes, gathers, storages and transports natural gas. The company's products include natural gas and natural gas liquids. It offers services such as natural gas, natural gas pipelines, and natural gas liquids gathering, processing, marketin …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆